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fild renal impairment is an important risk factor for late
ardiovascular complications. This substudy of the Lescol
ntervention Prevention Study (LIPS) assessed the effect
f fluvastatin on outcome of patients who had renal
ysfunction and those who did not. Complete data for
reatinine clearance calculation (Cockcroft-Gault for-
ula) were available for 1,558 patients (92.9% of the
IPS population). Patients were randomized to fluva-
tatin or placebo after successful completion of a first
ercutaneous coronary intervention. Follow-up time was
to 4 years. The effect of baseline creatinine clearance
n coronary atherosclerotic events (cardiac death, non-
atal myocardial infarction, and coronary reinterven-
ions not related to restenosis) was evaluated. Baseline
reatinine clearance (logarithmic transformation) was
nversely associated with an incidence of adverse events
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.01). However, no association was noted between cre-
tinine clearance and the incidence of adverse events
mong patients who received fluvastatin (hazard ratio
.0, 95% confidence interval 0.99 to 1.0, p  0.63). No
urther deterioration in creatinine clearance was ob-
erved during follow-up, regardless of baseline renal
unction or allocated treatment. Occurrence of adverse
vents was not related to changes in renal function
uring follow-up. Fluvastatin therapy markedly de-
reased the risk of coronary atherosclerotic events after
ercutaneous intervention in patients who had lower
alues of creatinine clearance at baseline. The benefit of
uvastatin was unrelated to any effect on renal
unction. 2005 by Excerpta Medica Inc.(Am J Cardiol 2005;95:445–451)n the recent Lescol Intervention Prevention Study
(LIPS), long-term therapy with fluvastatin de-
reased the incidence of cardiac events in patients who
nderwent percutaneous coronary intervention.1 The
resent study analyzed the results of LIPS to investi-
ate (1) the effect of baseline renal function on occur-
ence of long-term adverse events, (2) whether ther-
py with fluvastatin decreased the expected hazardous
ffect of renal impairment, (3) the effect of fluvastatin
n renal function during follow-up, and (4) the rela-
ion between changes in renal function over time and
he occurrence of adverse events.
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Study design and patient population: The study de-
ign and primary results of LIPS have been described
lsewhere.1 Briefly, after a first successful percutane-
us coronary intervention (residual stenosis 50%,
bsence of postprocedural in-hospital myocardial ne-
rosis, repeat revascularization, or death), patients
ere randomized to receive fluvastatin therapy
Lescol, Novartis Pharma AG, Basel, Switzerland; 40
g 2 times daily) or placebo for 3 to 4 years.
At enrollment, patients had to fulfill 1 of the
ollowing lipid profile criteria: (1) total cholesterol
evel of 135 to 270 mg/dl with a fasting triglyceride
evel 400 mg/dl, (2) total cholesterol level 212
g/dl for patients whose lipids levels were measured
4 hours to 4 weeks after an episode of myocardial
nfarction, or (3) total cholesterol level 232 mg/dl
or patients who had diabetes mellitus. Exclusion cri-
eria included a baseline serum creatinine value 1.8
g/dl. The study protocol was approved by the local
thics committees, and all patients gave informed
ritten consent.
Lipoproteins and evaluation of renal function: Each
atient was clinically evaluated 8 times after ran-
omization. Blood lipid levels were measured at all



























4nd at 52, 104, and 156 weeks. All biochemical anal-
ses were performed at a central laboratory (Analytico
edinet, Breda, The Netherlands). Creatinine clear-
nce was calculated according to the formula pro-
osed by Cockcroft and Gault2: creatinine clearance
milliliter/minute)  (140  age)  weight (kilo-
rams) 72 serum creatinine (milligrams/deciliter)
 0.85 for women).2
Clinical end points: Outcomes were evaluated as a
omposite of atherosclerotically related adverse car-
iac events, defined as the incidence of cardiac death
all deaths except those unequivocally related to a





(n  1,248) (n
Age (yrs) 58  9 6
Women 146 (12) 10
Height (cm) 170  8 16
Weight (kg) 79  11 6
Systolic blood pressure (mm Hg) 127  18 13
Diastolic blood pressure (mm Hg) 75  10 7
Risk factors and cardiovascular antecedents
Previous MI 540 (43) 14
Diabetes 152 (12) 3
Hypertension 435 (35) 15
Previous stroke 28 (2) 1
Peripheral vascular disease 62 (5) 3
Current smoker 363 (29) 5
Cholesterol-lowering diet 217 (17) 7
Family history of CAD 372 (30) 7
Ejection fraction (%) 62  11 6
Single-vessel disease 818 (66) 17
Multivessel disease 430 (35) 13
Clinical presentation
Stable angina* 618 (50) 16
Unstable angina 618 (50) 16
Treated vessel†
RCA 484 (30) 12
LAD 766 (47) 20
LCx 371 (23) 9
Lesions treated per patient 1.3  0.6 1.
Lesion type
A 325 (20) 7
B1 566 (35) 15
B2 540 (33) 15
C 185 (11) 5
Lesions treated with stent 910 (56) 24
Lipids (mg/dl)
Total cholesterol 200  31 20
LDL cholesterol 133  29 13
HDL cholesterol 37  12 3
Triglycerides 154  68 15
Serum creatinine (mg/dl) 1.11  1.7 1.3
Creatinine clearance (ml/min) 80  18 4
Baseline medication
ASA 1,221 (98) 29
Ticlopidine 862 (69) 23
ACE inhibitor 319 (26) 10
 Blocker 902 (72) 22
Values are mean  SD or numbers (percentages).
*Includes patients who had silent ischemia
†Categories are not mutually exclusive
ACE  angiotensin-converting enzyme; ASA  aspirin; CAD  coronary ather
 high-density lipoprotein; LAD  left anterior descending artery; LCx  left c
low-density lipoprotein; MI  myocardial infarction; RCA  right coronary arteoncardiac cause), nonfatal myocardial infarction i
46 THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 95(new pathologic Q waves or a total
plasma creatine kinase level 2
times the normal upper limit with the
MB isoenzyme), and all reinterven-
tions (surgical or percutaneous) not
caused by coronary restenosis occur-
ring after the index procedure. Ath-
erosclerotically related adverse car-
diac events were a predefined end
point of LIPS,1 based on the demon-
strated benefit of fluvastatin after
percutaneous intervention being un-
related to any effect of the drug on
restenosis.3 In addition, the incidence
of target lesion revascularization was
analyzed in the 2 renal function
groups.
Statistical analysis: All analyses
were carried out on an intent-to-treat
basis. Continuous variables were ex-
pressed as mean  SD and were
compared with Student’s unpaired t
test. Fisher’s exact test was used for
categorical variables, and Wilcox-
on’s scores were used for categorical
variables with an ordinal scale. Dis-
crete variables were expressed as
counts and percentages and were
compared in terms of relative risks
and 95% confidence intervals (CIs).
All statistical tests were 2-tailed.
Event-free survival distribution was
estimated according to the Kaplan-
Meier method, and overall incidence
of adverse events was tested with the
log-rank test. Cox’s proportional
hazards models were used to assess
decreased risk of adverse events.
For illustrative purposes, patients
were assigned to 1 of 2 groups ac-
cording to baseline value of creati-
nine clearance; abnormal creatinine
clearance was defined as a value in
the lowest quintile (55.9 ml/min).
This restrictive definition was ap-
plied in accordance with the LIPS
study protocol, which excluded pa-
tients who had markedly impaired
renal function. All testing to assess
he effect of renal function on outcomes was per-
ormed using baseline creatinine clearance as a con-
inuous numeric variable. Estimated risk ratios were
alculated from the observed data, with mean clear-
nce of the entire study population as a reference point
or the placebo group (risk ratio 1). Creatinine clear-
nce measurements were converted by logarithmic
ransformation to normalize distribution of the data.
All baseline clinical, angiographic, and procedural
haracteristics available in the study database were
ested to evaluate their relation to the incidence of





















































































































































d toultivariate analysis, and a final model was con-
tructed by stepwise selection of the most significant
ariables (the following variables were selected from
nivariate analyses: allocated treatment, creatinine
learance, stable/unstable angina, smoking status,
igh-density lipoprotein cholesterol levels, gender,
ypertension, diabetes, previous stroke, previous
yocardial infarction, cholesterol-lowering diet,
eight, body mass index, diastolic blood pressure,
ystolic blood pressure, multivessel disease, patho-
ogic Q wave in lead aVL, number of stents implanted,
nd number of sites with Thrombolysis In Myocardial
nfarction grade 3 flow).
Lipid profiles and clearance-time profile were an-
lyzed by analysis of covariance models that incorpo-
ated baseline values as covariates and added factors
f treatment, number of visits, and renal function
ubgroup with all possible interaction terms. To eval-
ate the relation between occurrence of clinical events
nd behavior of renal function over time, separate
nalyses were performed to evaluate the clearance-
ime profile for patients who had adverse events dur-
ng follow-up and those who did not.
ESULTS
Patient population: Between April 1996 and Octo-
er 1998, 1,677 patients were enrolled in the LIPS.
omplete data for creatinine clearance calculation
ere available for 1,558 patients (92.9%) and were
ncluded in the present study. Table 1 lists baseline
haracteristics of 1,248 patients who had normal renal
unction (creatinine clearance above the first quintile







Adverse coronary atherosclerotic events† 125 (20) 99
Cardiac death 14 (2) 7
Noncardiac death 0
All-cause death 14 (2) 7
Cardiac death/myocardial infarction 37 (6) 28
All-cause death/myocardial infarction 37 (6) 28
Values are numbers of patients (percentages).
*Placebo versus fluvastatin by Fisher’s exact test.
†Cardiac death, nonfatal myocardial infarction, and reinterventions not relate
TABLE 3 Risk of Adverse Coronary Atherosclerotic Events* at Fo
Transformation) at Baseline and Treatment Allocation (derived fr
Effect of fluvastatin treatment on the overall population
Effect of baseline creatinine clearance on the overall population (poo
treatment allocation)
Effect of baseline creatinine clearance on patients who received plac
Effect of baseline creatinine clearance on patients who received fluv
*Cardiac death, nonfatal myocardial infarction, and reinterventions not relater 55.9 ml/min) and of 310 patients who had im- a
CORONARY ARTERY DISEASE/FLUVASTATINaired renal function (creatinine clearance in the low-
st quintile or 55.9 ml/min). Overall, patients who
ad renal impairment were more likely to be older, to
e women, to be lighter and shorter, and to have more
evere coronary artery disease and co-morbidities.
Four groups were considered for analysis: (1) pa-
ients who had normal renal function and received
lacebo (n  617), (2) patients who had normal renal
unction and received fluvastatin (n  631), (3) pa-
ients who had impaired renal function and received
lacebo (n  160), and (4) patients who had impaired
enal function and received fluvastatin (n  150).
aseline characteristics did not differ between fluva-
tatin and placebo groups (pooled across renal func-
ion categories) except that patients who received flu-
astatin were taller (170  8 vs 169  8 cm, p 
.02) and heavier (77  11 vs 76  11 kg, p 0.01)
nd showed a higher prevalence of diabetes (14% vs
0%, p 0.01).
Cardiovascular events: Patients were followed for
mean of 3.8  0.1 years. Table 2 lists incidences
f coronary atherosclerotic events according to al-
ocated treatment and presence of renal impairment.
verall, fluvastatin therapy significantly decreased
he incidence of adverse events (hazard ratio 0.69,
5% CI 0.55 to 0.87, p  0.002; Table 3). More-
ver, baseline creatinine clearance (logarithmic
ransformation) was inversely associated with an
ncidence of adverse events in the overall popula-
ion pooled by treatment (hazard ratio 0.99, 95% CI
.98 to 0.99, p  0.02; Table 3). However, when







(n  150) p Value*
) 0.04 47 (29) 23 (15) 0.004
0.1 3 (2) 3 (20) 1.0
— 0 0 —
0.1 3 (2) 3 (2) 1.0
0.3 13 (8) 7 (5) 0.3
0.3 13 (8) 7 (5) 0.3
restenosis.
-up According to Creatinine Clearance (Logarithmic
Cox’s proportional hazards analysis)
Hazard Ratio
(95% CI) p Value
0.69 (0.55–0.87) 0.002
over 0.99 (0.98–0.99) 0.02
0.99 (0.98–0.99) 0.01














astanalyzed separately, baseline creatinine clearance






















































4as significantly associated with outcomes of pa-
ients who received placebo (hazard ratio 0.99, 95%
I 0.982 to 0.998, p  0.01), whereas no associa-
ion was noted among patients who received fluva-
tatin (hazard ratio 1.0, 95% CI 0.99 to 1.0, p 
.63; Table 3). Figures 1 and 2 show Kaplan-Meier
urves of patients who received fluvastatin or pla-
ebo grouped according to presence of renal impair-
ent or normal renal function. Among patients who
eceived placebo, curves of patients who had renal
mpairment versus those who did not began to di-
erge after approximately 1 year (p  0.009 by
og-rank test; Figure 2). Conversely, among patients
ho received fluvastatin, curves of adverse events
f patients who had renal impairment versus those
f patients who had normal renal function remained
verlapped throughout follow-up (p  0.92 by log-
ank test; Figure 2). No differences were observed
n the incidence of repeat revascularization due to
IGURE 1. Cumulative risk of atherosclerotically related adverse
ardiac events (cardiac death, nonfatal myocardial infarction,
nd all reinterventions not caused by coronary restenosis) in pa-
ients who had renal impairment (top) versus those who had nor-
al renal function (bottom) who received placebo or fluvastatin.estenosis between patients who had renal impair- c
48 THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 95ent and those who did not (4.4% vs 5.2%, respec-
ively, p  0.7).
Lipoprotein levels and renal function outcome: Base-
ine lipoprotein levels were similar in the 2 renal
unction groups, with the exception of high-density
ipoprotein cholesterol levels (Table 1). By 6 weeks,
uvastatin significantly decreased levels of low-den-
ity lipoprotein cholesterol compared with placebo in
atients who had renal impairment (median change
ith fluvastatin 24%, 95% CI 28 to 20 vs
13%, 95% CI 9 to 17, p 0.001) and those who
ad normal renal function (28%, 95% CI 30 to
25% vs 11%, 95% CI 9 to 13%, p 0.001).
he decrease was similar in patients who had renal
mpairment and those who did not and was maintained
hroughout the study. At the end of the study, no
ignificant differences in triglyceride levels were ob-
erved between treatment groups. Levels of high-den-
ity lipoprotein cholesterol increased by a median of
2%, regardless of treatment allocation or baseline
enal function.
Renal function remained stable throughout fol-
ow-up and the predicted clearance-time profile was
ot influenced by fluvastatin therapy, regardless of
aseline creatinine clearance (Figure 3). No signifi-
IGURE 2. Cumulative risk of atherosclerotically related adverse
ardiac events (cardiac death, nonfatal myocardial infarction,
nd all reinterventions not caused by coronary restenosis) in pa-
ients who received placebo (top) versus those who received flu-



















































catients who had adverse events during follow-up and
hose who did not (Figure 3).
Predictors of increased cardiovascular risk: Figure 4
hows estimated risk ratios according to baseline cre-
tinine clearance calculated by Cox’s proportional
azards model from the observed data (mean clear-
IGURE 3. Predicted changes in creatinine clearance (milliliters/
inute) throughout follow-up in patients who had been random-
zed to receive placebo or fluvastatin. Four baseline clearance
evels are shown: 47 ml/min (actual mean clearance of patients
ho had renal impairment), 80 ml/min (actual mean clearance
f patients who had normal renal function), 33 ml/min (mean
learance of patients who had renal impairment 2 SD), and
16 ml/min (mean clearance of patients who had normal renal
unction 2 SD). Changes in renal function are shown for the
ntire population (top), patients who did not develop adverse
vents (middle), and patients who developed >1 adverse event
uring follow-up (bottom).nce of the entire study population was chosen as a f
CORONARY ARTERY DISEASE/FLUVASTATINeference point for the placebo group, risk ratio 1). A
rogressive increase in the risk of long-term compli-
ations is predicted with lower values of creatinine
learance. However, fluvastatin therapy caused a
ownward shift and flattening of the entire risk ratio
urve. Interestingly, a risk ratio of 1 was associated
ith a baseline creatinine clearance of 	70 ml/min in
he placebo group but with a rate of only 25 ml/min in
he fluvastatin group.
Multivariate Cox’s proportional hazards analysis
dentified creatinine clearance as an independent pre-
ictor of atherosclerotically related adverse cardiac
vents (Table 4). Other variables significantly associ-
ted with an incidence of adverse events included
uvastatin therapy, diabetes mellitus, multivessel dis-
ase, and number of stents implanted during a proce-
ure (Table 4).
ISCUSSION
The major finding of the present study is that low
alues of creatinine clearance at baseline significantly
ncreases the incidence of coronary adverse athero-
clerotic events after a first successful percutaneous
oronary intervention and that this effect is virtually
bolished by long-term therapy with fluvastatin. The
enefit of fluvastatin in patients who have renal im-
airment could not be explained by a differential
ction on lipid levels or on renal function during
IGURE 4. Estimated risk ratios as a function of creatinine clear-
nce (millimeters/minute) in patients who had been randomized
o receive fluvastatin or placebo. Hazard ratio curves were esti-
ated according to Cox’s proportional hazards model (risk ra-
ios were calculated with the mean creatinine clearance of the
ntire study population chosen as a reference point for the pla-
ebo group, risk ratio 1).
TABLE 4 Multivariate Predictors of Adverse Coronary
Atherosclerotic Events at Follow-up
Hazard Ratio
(95% CI) p Value
Fluvastatin therapy 0.66 (0.52–0.83) 0.0005
Diabetes mellitus 1.57 (1.14–2.16) 0.006
Multivessel disease 1.33 (1.04–1.69) 0.02
No. of stents implanted 1.25 (1.04–1.51) 0.02
Creatinine clearance* 0.63 (0.42–0.95) 0.03
*Logarithmic transformation.ollow-up. Moreover, no association was observed
























































































































4etween the incidence of adverse events and changes
n renal function during follow-up.
In addition to procedures to alleviate symptoms
nd myocardial ischemia, secondary prevention of
urther adverse events constitutes a key paradigm in
he long-term management of patients who have di-
gnosed coronary disease. Although the need for re-
eat intervention has been recognized as the major
imitation of angioplasty, the newly introduced drug-
luting stents have been shown to markedly decrease
estenosis rates.4 In this context, adoption of proce-
ures aimed at modifying the natural course of ath-
rosclerotic disease (i.e., non–restenosis-related com-
lications) becomes the main focus of attention after
ercutaneous control. In the present study, fluvastatin
as shown to significantly decrease the incidence of
dverse events after angioplasty in patients who had
enal dysfunction and those who did not.
Secondary prevention strategies constitute a
ange of methods to decrease the effect of known
isk factors on outcomes of patients who have di-
gnosed coronary disease. Ideally, management of a
articular risk factor should decrease the risk of
atients who receive treatment to the level of sub-
ects who do not have the condition. Mild renal
mpairment has been identified as an important pre-
ictor of adverse events in patients who have pre-
ious cardiovascular disease.5–12 Although diuretic-
ased blood pressure control and long-term ramipril
herapy have been reported to improve clinical out-
omes, the hazardous effect of mild renal impair-
ent was only partly decreased by these thera-
ies.11,13 Pravastatin has recently been shown to
ecrease the incidence of events in patients who
ave renal dysfunction; in contrast to most reports,
he presence of renal impairment did not influence
ate clinical outcomes in that study.14 Moreover, the
xtent to which statins decreased the risk of future
omplications was not evaluated in relation to pa-
ients who had normal renal function.14 In the
resent study, renal impairment significantly and
ndependently impaired long-term clinical out-
omes after coronary intervention. Notably, fluva-
tatin therapy equalized outcomes of patients who
ad renal impairment and those who had normal
enal function, thus virtually abolishing the hazard-
us effect of renal dysfunction.
In contrast to previous studies,15 no effect of flu-
astatin therapy on renal function was observed dur-
ng the 4-year follow-up. These results suggest that
he benefit of fluvastatin was not mediated by a direct
ffect to stabilize or improve creatinine clearance.
oreover, occurrence of adverse events was not re-
ated to changes in renal function. In addition, the
ffect of fluvastatin in patients who had renal dysfunc-
ion could not be explained by a more pronounced
ipid decrease in this group. These results suggest that
he benefit of statins in patients who have renal im-
airment may be associated with mechanisms that are
ot related to a direct effect on kidney physiology and
re independent of their lipid-lowering effects. Al-
hough not assessed in the present study, statins have
i
h
50 THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 95een widely reported to exert beneficial effects on a
ariety of pathophysiologic atherogenic mechanisms
hat are altered in patients who have renal impair-
ent.16–24
Study limitations: The present findings may not be
xtrapolated to all patients who have coronary heart
isease, because only patients who underwent suc-
essful elective percutaneous interventions were in-
luded. Therefore, medically and surgically treated
atients and those who had unsuccessful procedures
ere not represented in this study population. Further,
he effect of fluvastatin in patients who had severe
enal impairment was not assessed in the present
tudy, and more detailed investigations of the nature
f renal impairment (e.g., diagnosis of underlying
enal pathology or assessment of microalbuminuria or
roteinuria) and measurements of biochemical
roatherogenic markers were not available. These lim-
tations do not alter the overall conclusion that fluva-
tatin therapy had a clinically relevant effect in pa-
ients who had mild renal impairment.
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